Edesa Biotech, Inc.

Rentabilité sur six mois: +0.5236%
Rendement en dividendes: 0%
Secteur: Healthcare

1.92 $

0 $ 0%
1.59 $
5.42 $

paper.min_max_per_year

Calendrier des promotions Edesa Biotech, Inc.

À propos de l'entreprise Edesa Biotech, Inc.

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that is in Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.

Paramètres de base

IPO date
2015-11-05
ISIN
CA27966L1085
Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Сайт

Grade

Sous-estimation
Nom Signification Grade
P/S 0 0
P/BV 7.18 1
P/E 0 0
Efficacité
Nom Signification Grade
ROA -97.13 0
ROE -136.66 0
ROIC 0 0
Dividendes
Nom Signification Grade
Rendement en dividendes 0 0
DSI 0 0
Croissance moyenne du dividende 0 0
Devoir
Nom Signification Grade
Debt/EBITDA -0.0033 10
Debt/Ratio 0.0052 10
Debt/Equity 0.9251 9
Impulsion de croissance
Nom Signification Grade
Rentabilité Revenue, % 44.12 6
Rentabilité Ebitda, % -6.51 0
Rentabilité EPS, % 160.98 10

paper.price.prices

Prix Common.min. Common.max. Changement paper.changes_in_industry paper.changes_in_index
common.calendar.number_days.1 1.92 $ 0 $ 0 $ 0 % 0 % 0 %
common.calendar.number_days.7d 1.86 $ 0 $ 0 $ 3.23 % 0 % 0 %
common.calendar.number_days.30d 1.96 $ 1.83 $ 1.96 $ -2.04 % 0 % 0 %
common.calendar.number_days.90d 2.25 $ 1.83 $ 2.4 $ -14.67 % 0 % 0 %
common.calendar.number_days.180d 1.91 $ 1.59 $ 3.25 $ 0.52 % 0 % 0 %
common.calendar.number_days.1y 4.34 $ 1.59 $ 5.42 $ -55.76 % 0 % 0 %
common.calendar.number_days.3y 1.9 $ 0.77 $ 30.63 $ 1.05 % 0 % 0 %
common.calendar.number_days.5y 7.07 $ 0.77 $ 30.63 $ -72.84 % 0 % 0 %
common.calendar.number_days.10y 0.53 $ 0.53 $ 30.63 $ 362.26 % 0 % 0 %
common.calendar.number_days.ytd 1.95 $ 1.59 $ 3.25 $ -1.54 % 0 % 0 %

Principaux propriétaires

Entreprises similaires



Gestion d'entreprise

Superviseur Titre d'emploi Paiement Année de naissance
Dr. Pardeep Nijhawan FRCPC, M.D. CEO, Company Secretary & Director 475.33k 1971 (54 année)
Dr. Michael J. Brooks M.B.A., Ph.D. President 439.27k 1978 (47 années)
Mr. Stephen L. Lemieux BA, CPA, CA, CPA, MMPA Chief Financial Officer 402.86k 1977 (48 années)

Informations sur l'entreprise

Adresse: Canada, Markham. ON LR H, 100 Spy Court - Ouvrir dans google maps, Ouvrir les cartes yandex
Site web: https://www.edesabiotech.com